Prevention of Experimental Choroidal Neovascularization With Intravitreal Anti–Vascular Endothelial Growth Factor Antibody Fragment
Top Cited Papers
Open Access
- 1 March 2002
- journal article
- laboratory sciences
- Published by American Medical Association (AMA) in Archives of Ophthalmology (1950)
- Vol. 120 (3) , 338-346
- https://doi.org/10.1001/archopht.120.3.338
Abstract
CHOROIDAL neovascularization (CNV) is the major cause of severe visual loss in patients with age-related macular degeneration (AMD). New blood vessels grow from the choroid and penetrate through the Bruch membrane into the subretinal pigment epithelial and subretinal space. These vessels can leak and bleed, leading to exudative retinal detachment and hemorrhage. Eventually, this process progresses to a fibrovascular scar with destruction of photoreceptors and vision loss.Keywords
This publication has 6 references indexed in Scilit:
- Lutetium texaphyrin (Lu-Tex): a potential new agent for ocular fundus angiography and photodynamic therapyAmerican Journal of Ophthalmology, 2000
- Comparisons of the Intraocular Tissue Distribution, Pharmacokinetics, and Safety of 125I-Labeled Full-Length and Fab Antibodies in Rhesus Monkeys Following Intravitreal AdministrationToxicologic Pathology, 1999
- Intravenous Infusion of Liposomal Benzoporphyrin Derivative for Photodynamic Therapy of Experimental Choroidal NeovascularizationArchives of Ophthalmology (1950), 1996
- Inhibition of Vascular Endothelial Growth Factor Prevents Retinal Ischemia—Associated Iris Neovascularization in a Nonhuman PrimateArchives of Ophthalmology (1950), 1996
- Vascular endothelial growth factor, a specific regulator of angiogenesisCurrent Opinion in Nephrology and Hypertension, 1996
- Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal DisordersNew England Journal of Medicine, 1994